| 2023-07-21 |
股东大会：
将于2023-08-14召开股东大会
会议内容 ▼▲
- 1.To consider and vote upon a proposal to approve the resolutions attached hereto as Exhibit A, approving and authorizing the Board’s determination to effect the transfer of all or substantially all of Aceragen’s assets through an assignment for the benefit of creditors (the “Assignment,” and such proposal, the “Assignment Proposal”).
2.To grant discretionary authority to Aceragen’s board of directors (the “Board”) to adjourn the Special Meeting, from time to time, to a later date or dates, even if a quorum is present, to solicit additional proxies in the event that there are insufficient shares present in person or by proxy voting in favor of the Assignment Proposal (the “Adjournment Proposal”).
3.To transact such other business as may properly come before the Special Meeting or any adjournments, postponements or continuations thereof.
|
| 2023-07-21 |
详情>>
股本变动：
变动后总股本842.03万股
|
| 2023-06-29 |
详情>>
业绩披露：
2023年一季报每股收益-2.94美元,归母净利润-2186.7万美元,同比去年增长-423.38%
|
| 2023-04-13 |
详情>>
业绩披露：
2022年年报每股收益-7.18美元,归母净利润-2336万美元,同比去年增长-124.1%
|
| 2022-12-08 |
股东大会：
将于2023-01-12召开股东大会
会议内容 ▼▲
- 1.To approve, in accordance with Nasdaq Listing Rule 5635(a), the issuance of shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), upon conversion of the Company’s Series Z Non-Voting Convertible Preferred Stock, par value $0.01 per share (“Series Z Preferred Stock”), issued in September 2022 (the “Conversion Proposal” or “Proposal No. 1”);
2.To approve an amendment to the Restated Certificate of Incorporation to effect a reverse stock split of the Common Stock at a ratio to be determined by the Company’s Board of Directors (the “Board of Directors”) within a range of one-for-seventeen (1:17) and one-for-twenty-three (1:23) (or any number in between), to be effected in the sole discretion of the Board of Directors at any time within one year of the date of the Special Meeting without further approval or authorization from the Company’s stockholders (the “Reverse Stock Split Proposal” or “Proposal No. 2”);
3.To approve the Idera Pharmaceuticals, Inc. 2022 Stock Incentive Plan (the “Equity Compensation Plan Proposal” or “Proposal No. 3”);
4.To approve the adjournment or postponement of the Special Meeting, if necessary, to continue to solicit votes for Proposal Nos. 1, 2, and/or 3 (the “Adjournment Proposal” or “Proposal No. 4”).
|
| 2022-11-14 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-0.24美元,归母净利润-1258.4万美元,同比去年增长-112.51%
|
| 2022-08-09 |
详情>>
业绩披露：
2022年中报每股收益-0.18美元,归母净利润-948.5万美元,同比去年增长-108.99%
|
| 2022-05-05 |
详情>>
业绩披露：
2022年一季报每股收益-0.08美元,归母净利润-417.8万美元,同比去年增长-103.81%
|
| 2022-04-29 |
股东大会：
将于2022-06-23召开股东大会
会议内容 ▼▲
- 1.Elect two Class III directors to our board of directors for terms to expire at the 2025 annual meeting of stockholders;
2.Approve, by non-binding vote, the compensation of the Company’s named executive officers for 2021;
3.Ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
4.Approve the amendment to the 2013 Stock Incentive Plan to increase the number of authorized shares;
5.Approve the amendment to the 2017 Employee Stock Purchase Plan to increase the number of authorized shares;
6.Transact any other business as may properly come before the Annual Meeting or any postponement, continuation or adjournment of the Annual Meeting.
|
| 2022-03-31 |
详情>>
业绩披露：
2020年年报每股收益-3.33美元,归母净利润-1.13亿美元,同比去年增长-33.24%
|
| 2022-03-31 |
详情>>
业绩披露：
2019年年报每股收益-2.96美元,归母净利润-8455.8万美元,同比去年增长-41.21%
|
| 2022-03-31 |
详情>>
业绩披露：
2021年年报每股收益1.97美元,归母净利润9694.10万美元,同比去年增长186.05%
|
| 2021-11-08 |
详情>>
业绩披露：
2021年三季报(累计)每股收益2.10美元,归母净利润1.01亿美元,同比去年增长379.68%
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-08-09 |
详情>>
业绩披露：
2021年中报每股收益2.31美元,归母净利润1.05亿美元,同比去年增长784.34%
|
| 2021-04-29 |
详情>>
业绩披露：
2021年一季报每股收益2.66美元,归母净利润1.10亿美元,同比去年增长1143.12%
|
| 2021-04-28 |
股东大会：
将于2021-06-08召开股东大会
会议内容 ▼▲
- 1.Elect two Class II directors to our board of directors for terms to expire at the 2024 annual meeting of stockholders;
2.Approve, by non-binding vote, the compensation of the Company’s named executive officers for 2020;
3.Ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021;
4.Transact any other business as may properly come before the 2021 annual meeting or any postponement or adjournment of the 2021 annual meeting.
|
| 2020-04-06 |
股东大会：
将于2020-05-12召开股东大会
会议内容 ▼▲
- 1.Elect three Class I directors to our board of directors for terms to expire at the 2023 annual meeting of stockholders;
2.Approve, by non-binding vote, the compensation of the Company's named executive officers for 2019;
3.Approve an amendment to our Restated Certificate of Incorporation to increase the authorized number of shares of common stock;
4.Ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020;
5.Transact any other business as may properly come before the 2020 annual meeting or any postponement or adjournment of the 2020 annual meeting.
|
| 2019-04-25 |
股东大会：
将于2019-06-04召开股东大会
会议内容 ▼▲
- 1.Elect two Class III directors to our board of directors for terms to expire at the 2022 annual meeting of stockholders;
2.Approve, by non-binding vote, executive compensation;
3.Approve an amendment to our 2013 Stock Incentive Plan to increase the number of shares authorized for issuance thereunder;
4.Approve an amendment to our 2017 Employee Stock Purchase Plan to increase the number of shares authorized for issuance thereunder;
5.Ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019;
6.Transact any other business as may properly come before the 2019 annual meeting or any postponement or adjournment of the 2019 annual meeting.
|
| 2018-05-22 |
股东大会：
将于2018-06-20召开股东大会
会议内容 ▼▲
- 1.Elect three Class II directors to our board of directors for terms to expire at the 2021 annual meeting of stockholders;
2.Approve an amendment to our Restated Certificate of Incorporation, as amended, to effect a reverse stock split of our issued and outstanding common stock by a whole number ratio of not less than 1-for-4 and not more than 1-for-8, such ratio and the implementation and timing of such reverse stock split to be determined in the discretion of our board of directors at any time prior to our 2019 annual meeting of stockholders, and, in connection therewith, to decrease the number of authorized shares of our common stock on a basis proportional to the reverse stock split ratio;
3.Approve an amendment to our Restated Certificate of Incorporation, as amended, to set the number of authorized shares of our common stock at a number determined by calculating the product of 280,000,000 multiplied by two times (2x) the reverse stock split ratio. This Proposal Three is subject to approval by our stockholders of the amendment to our Restated Certificate of Incorporation, as amended, effecting the reverse stock split as set forth in Proposal Two and, therefore, will not be implemented unless Proposal Two is approved and such reverse stock split is implemented;
4.Approve, by non-binding vote, executive compensation;
5.Ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018;
6.Transact any other business as may properly come before the 2018 annual meeting or any postponement or adjournment of the 2018 annual meeting.
|
| 2017-11-17 |
股东大会：
将于2018-01-04召开股东大会
会议内容 ▼▲
- 1.approve an amendment to our Restated Certificate of Incorporation, as amended, to effect a reverse stock split of our issued and outstanding common stock by a whole number ratio of not less than 1-for-4 and not more than 1-for-8, such ratio and the implementation and timing of such reverse stock split to be determined in the discretion of our board of directors at any time prior to our 2018 annual meeting of stockholders, and, in connection therewith, to decrease the number of authorized shares of our common stock on a basis proportional to the reverse stock split ratio;
2.approve an amendment to our Restated Certificate of Incorporation, as amended, to set the number of authorized shares of our common stock at a number determined by calculating the product of 280,000,000 multiplied by two times (2x) the reverse stock split ratio. This Proposal No. 2 is subject to approval by our stockholders of the amendment to our Restated Certificate of Incorporation, as amended, effecting the reverse stock split as set forth in Proposal No. 1 and, therefore, will not be implemented unless Proposal No. 1 is approved and such reverse stock split is implemented.
|
| 2017-04-28 |
股东大会：
将于2017-06-07召开股东大会
会议内容 ▼▲
- 1.Elect three Class I directors to our board of directors for terms to expire at the 2020 annual meeting of stockholders;
2.Approve, by non-binding vote, executive compensation;
3.Approve, by non-binding vote, the frequency (one year, two years or three years) of future executive compensation advisory votes;
4.Approve an amendment to our 2013 Stock Incentive Plan to increase the number of shares authorized for issuance under our 2013 Stock Incentive Plan and make certain other amendments as are set forth in Appendix A to the accompanying proxy statement;
5.Approve our 2017 Employee Stock Purchase Plan;
6.Ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017;
7.Transact any other business as may properly come before the 2017 annual meeting or any postponement or adjournment of the 2017 annual meeting.
|
| 2016-04-25 |
股东大会：
将于2016-06-13召开股东大会
会议内容 ▼▲
- 1.Elect three Class III directors to our board of directors for terms to expire at the 2019 annual meeting of stockholders;
2.Approve, by non-binding vote, executive compensation;
3.Ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016;
4.Transact any other business as may properly come before the 2016 annual meeting or any postponement or adjournment of the 2016 annual meeting.
|
| 2015-04-29 |
股东大会：
将于2015-06-08召开股东大会
会议内容 ▼▲
- 1.Elect two Class II directors to the company's board of directors for terms to expire at the 2018 annual meeting of stockholders;
2.Approve, by non-binding vote, executive compensation;
3.Approve an amendment to the company's 2013 Stock Incentive Plan to increase the number of shares of common stock authorized for issuance under the company's 2013 Stock Incentive Plan and make certain other changes related to the vesting of awards issued under the company's 2013 Stock Incentive Plan, as set forth in Appendix A attached to the accompanying proxy statement;
4.Ratify the selection of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2015;
5.Transact any other business as may properly come before the 2015 annual meeting or any postponement or adjournment of the 2015 annual meeting.
|
| 2014-04-30 |
股东大会：
将于2014-06-09召开股东大会
会议内容 ▼▲
- 1. Elect two Class I directors to our board of directors for terms to expire at the 2017 annual meeting of stockholders;
2. Approve, by non-binding vote, executive compensation;
3. Approve an amendment to our 2013 Stock Incentive Plan to increase the number of shares authorized for issuance thereunder from an aggregate of 4,224,460 shares of common stock plus such additional number of shares of common stock (up to 5,720,540 shares) as is equal to the number of shares of common stock subject to awards granted under our 2008 Stock Incentive Plan which awards expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by us at their original issuance price pursuant to a contractual repurchase right, to an aggregate of up to 10,224,460 shares of common stock plus such additional number of shares of common stock (up to 5,720,540 shares) as is equal to the number of shares of common stock subject to awards granted under the 2008 Stock Incentive Plan which awards expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by us at their original issuance price pursuant to a contractual repurchase right;
4. Ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2014;
5. Transact any other business as may properly come before the 2014 annual meeting or any postponement or adjournment of the 2014 annual meeting.
|